No Data
Shandong Sinobioway Biomedicine (002581.SZ): Granted 19.6346 million stock Options to 100 incentive targets.
On December 23, Gelonghui reported that Shandong Sinobioway Biomedicine (002581.SZ) announced that the granting conditions stipulated in the "2024 Stock Options Incentive Plan (Draft) of Shandong Sinobioway Biomedicine Co., Ltd." have been met. According to the authorization of the fourth extraordinary Shareholders' Meeting of Shandong Sinobioway Biomedicine Co., Ltd. in 2024, the company held the 31st meeting of the 5th Board of Directors and the 21st meeting of the 5th Board of Supervisors on December 20, 2024, to review and approve the "Proposal on Granting Stock Options to the Incentive Objectives of the Company's 2024 Stock Options Incentive Plan," agreeing to use December 2024.
Despite Currently Being Unprofitable, Shandong Sinobioway Biomedicine (SZSE:002581) Has Delivered a 88% Return to Shareholders Over 5 Years
Shandong Sinobioway Biomedicine (002581.SZ) has appointed Zhou Ting as the financial director.
Shandong Sinobioway Biomedicine (002581.SZ) announced that the company's board of directors recently received a report from the Chief Financial Officer, Mr. Liu Yangjun...
Shandong Sinobioway Biomedicine (002581.SZ) plans to launch a stock options incentive plan for 2024, with an exercise price of 12.35 yuan per share.
Shandong Sinobioway Biomedicine (002581.SZ) has announced the 2024 stock options incentive plan (draft), which grants...
We're Not Very Worried About Shandong Sinobioway Biomedicine's (SZSE:002581) Cash Burn Rate
Unnamed Pharmaceuticals: Report for the third quarter of 2024
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
No Data
